Current Issue

  • Image of Hematology 2023-09-30

    0 596 192

    Persistent polyclonal B-cell lymphocytosis with buttock-like cells mimicking follicular lymphoma

    Fnu Aakash, Sa A Wang, Karan Saluja, Beenu Thakral

    Blood Res 2023; 58(3): 125-125
  • Image of Hematology 2023-09-30

    0 390 146

    Intrasinusoidal proerythroblast infiltration in therapy related myeloid neoplasm

    Jian Li, Merit Hanna

    Blood Res 2023; 58(3): 126-126
  • Original Article 2023-09-30

    0 799 214

    Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital

    Mahnaz Yadollahi, Hessam Hosseinalipour, Mehrdad Karajizadeh, Muhammad Alinaqi, Pooria Fazeli, Mehrdad Jowkar, Kazem Jamali, Maryam Yadollahi

    Blood Res 2023; 58(3): 127-132

    Abstract : Background
    Pulmonary thromboembolism (PTE) is a significant contributing factor to vascular diseases. This study aimed to determine the prevalence of pulmonary thromboembolism and its predisposing factors in patients with COVID-19.
    This cross-sectional study included 284 patients with COVID-19 who were admitted to Nemazee Teaching Hospital (Shiraz, Iran) between June and August 2021. All patients were diagnosed with COVID-19 by a physician based on clinical symptoms or positive polymerase chain reaction (PCR) test results. The collected data included demographic data and laboratory findings. Data were analyzed using the SPSS software. P≤0.05 was considered statistically significant.
    There was a significant difference in the mean age between the PTE group and non-PTE group (P=0.037). Moreover, the PTE group had a significantly higher prevalence of hypertension (36.7% vs. 21.8%, P=0.019), myocardial infarction (4.5% vs. 0%, P=0.006), and stroke (23.9% vs. 4.9%, P=0.0001). Direct bilirubin (P=0.03) and albumin (P=0.04) levels significantly differed between the PTE and non-PTE groups. Notably, there was a significant difference in the partial thromboplastin time (P=0.04) between the PTE and non-PTE groups. A regression analysis indicated that age (OR, 1.02; 95% CI, 1.00‒1.004; P=0.005), blood pressure (OR, 2.07; 95% CI, 1.12‒3.85; P=0.02), heart attack (OR, 1.02; 95% CI, 1.28‒6.06; P=0.009), and albumin level (OR, 0.39; 95% CI, 0.16‒0.97; P=0.04) were all independent predictors of PTE development.
    Regression analysis revealed that age, blood pressure, heart attack, and albumin levels were independent predictors of PTE.

  • Original Article 2023-09-30

    0 689 196

    Abstract : Background
    Epigenetic studies, particularly research on microRNA (miRNA), have flourished. The abnormal expression of miRNA contributes to the development of hematologic malignancies. miR-765 has been reported to inhibit cell proliferation by downregulating proteolipid protein 2 (PLP2), which causes apoptosis. We investigated miR-765 dysregulation in myelodysplastic syndromes (MDS).
    We compared the expression profiles of miR-765 in 65 patients with MDS and 11 controls. Cell proliferation and apoptosis assays were performed to determine the in vitro effects of miR-765 on leukemia cells transfected with the miR-765 mimic. Reverse transcription quantitative PCR (RT-qPCR) and western blotting were performed to examine the targets of miR-765.
    We found that miR-765 levels were upregulated 10.2-fold in patients with MDS compared to controls. In refractory cytopenia with multilineage dysplasia, the percentage of patients with elevated miR-765 levels was significantly higher than in other forms of MDS. Experiments with leukemia cells revealed that transfection with a miR-765 mimic inhibited cell proliferation and induced apoptosis. RT-qPCR and western blotting demonstrated that the target of miR-765 was PLP2.
    These findings imply that upregulation of miR-765 induces apoptosis via downregulation of PLP2 and may have a role in MDS pathogenesis.

  • Original Article 2023-09-30

    0 628 96

    ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review

    Alexander T. Phan, Ari A. Ucar, Aldin Malkoc, Janie Hu, Luke Buxton, Alan W. Tseng, Fanglong Dong, Julie P.T. Nguyễn, Arnav P. Modi, Ojas Deshpande, Johnson Lay, Andrew Ku, Dotun Ogunyemi, Sarkis Arabian

    Blood Res 2023; 58(3): 138-144

    Abstract : Background
    Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.
    This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).
    The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (P<0.001). There was statistically significant association between combined ABO and RH blood type and mortality (P=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (P=0.005). The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.
    ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.

  • Letter to the Editor 2023-09-30

    0 685 176

    Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease

    Hyun Min Kim, Joonyeop Lee, Seokjin Kim, Jong Wook Lee, Hee-Je Kim, Young-Seok Cho

    Blood Res 2023; 58(3): 145-148
  • Letter to the Editor 2023-09-30

    0 271 133

    Hairy cell leukemia presenting as a pleural mass without leukemic component: a case report

    Ahmad Alshomrani, Jeffrey J. Cannatella, Hina Qureishi

    Blood Res 2023; 58(3): 148-151
  • Letter to the Editor 2023-09-30

    0 317 158

    Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report

    Suji Park, Jae-Ryong Shim, Ji Hyun Lee, Jin-Yeong Han

    Blood Res 2023; 58(3): 151-155
  • Letter to the Editor 2023-09-30

    0 366 173

    Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm

    Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Youngil Koh

    Blood Res 2023; 58(3): 155-157
  • Letter to the Editor 2023-09-30

    0 356 60

    A challenging diagnosis of hepatosplenic T cell lymphoma in a 10-year-old child

    Sadiq Khalaf Ali, Saad Abdulbaqi Alomar, Hussam Mahmood Salih, Nooran Salem Yaseen

    Blood Res 2023; 58(3): 157-161
  • Letter to the Editor 2023-09-30

    1 339 87

    Atypical posterior reversible encephalopathy syndrome secondary to dasatinib

    Amiya Ranjan Nayak, Deepika Yadav, Priyanka Naranje, Jasmita Dass, Pradeep Kumar, Mukul Aggarwal

    Blood Res 2023; 58(3): 161-163
  • Erratum 2023-09-30

    0 156 43


    Blood Res 2023; 58(3): 164-164
Blood Res
Sep 30, 2023 Vol.58 No.3, pp. 125~164

Most KeyWord ?

What is Most Keyword?

  • It is most registrated keyword in articles at this journal during for 2 years.

Most Read

Most Cited

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download